Aqilion – Disrupting the Vicious Cycle of Chronic Inflammation
Chronic inflammation is an underlying cause of many diseases and represents an immense societal burden. Researchers continue to struggle to solve the riddle behind...
The CAR T revolution in the fight against cancer
CAR T-cell therapies have shown transformational potential for the treatment of cancer, generating excitement among researchers and oncologists. Six CAR T drugs have been...
BioStock Investor Pitch: Spermosens
Swedish Spermosens’ vision is to improve diagnostics within the area of male infertility and thus help improve IVF treatments. Using the company’s JUNO-Checked system...
Promore Pharma’s CEO on hopes for 2023
For Solna-based Promore Pharma, 2022 was characterised by steady advancement in the development of its drug candidate ensereptide. During the year, the company carried...
Sweden’s 10 strongest life science stocks 2022
2022 was a tough year for many life science investors, who not only witnessed several drops, but also sharp drops in the value of...
New drugs bring hope to ALS patients
Recently, attention has again been focused on ALS. The fatal neurological disease has long been one of the biggest medical mysteries. Today, the knowledge...
A breakthrough in Alzheimer’s drug development?
As the societal burden of Alzheimer’s disease continues to grow, drug development in the field has struggled to keep up the pace. A huge...
Patient perspective in focus in Abliva’s phase II/III study
Biotech company Abliva is now preparing for the perhaps biggest step in the company's history to date – a pivotal phase II/III study with...
BioStock Investor Meeting: Interview with Lipum
Biopharmaceutical company Lipum is approaching clinical studies with the candidate SOL-116, which targets chronic inflammatory diseases such as rheumatoid arthritis. CEO Einar Pontén presented the...
Top 5 life science stocks – first half of 2022
For known reasons, it has been a rough first half of the year for the stock market. Several of the world's leading indices lost...